Malaysia Pharma and Healthcare Sector Report 2023-2024

Malaysia has one of Southeast Asia's most advanced pharmaceuticals and healthcare sectors. The Malaysian healthcare system comprises two well-developed segments: a taxpayer-funded and government-run system and a private sector. The public system, run by the Ministry of Health (MoH), is the lynchpin of Malaysia's healthcare provision, rendering heavily-subsidised healthcare services to most of the population. The public healthcare system relies on a referral model, where patients access higher-tier services only after consultation with general practitioners or outpatient departments reveals that their treatment requires more specialist skills or advanced equipment. Meanwhile, private healthcare providers allow fee-paying patients to access specialist doctors directly, expediting their treatment but contributing to instances of excessive testing and treatment.

This report provides a complete and detailed analysis of the "Healthcare and pharma" sector for Malaysia. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Healthcare and pharma" sector in Malaysia
• Crystallise the forces both driving and restraining this sector in Malaysia
• Ascertain Malaysia’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Malaysia.
• Build a clear picture of trends, output and consumption for specific sub-sectors